Daniel Zhang

9PUBLICATIONS
29CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMicrobial taxonomyMechanobiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 23, 2023
Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade.

Crismita Dmello, Junfei Zhao, Li Chen

|May 13, 2022
Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma.

Crismita Dmello, Aarón Sonabend, Victor A Arrieta

|Feb 12, 2022
Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.

Víctor A Arrieta, Andrew X Chen, J Robert Kane

|Feb 05, 2022
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.

Víctor A Arrieta, Andrew X Chen, J Robert Kane

|Jan 07, 2022
Ultrasound-mediated blood-brain barrier opening increases cell-free DNA in a time-dependent manner.

Daniel Y Zhang, Andrew Gould, Hannah C Happ

|Aug 26, 2021
TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas.

Edgar Gonzalez-Buendia, Junfei Zhao, Lu Wang

Pageof 2

Frequent Collaborators

7 joint publications

Adam M Sonabend

3 joint publications

Brice Laffleur

3 joint publications

Raul Rabadan

3 joint publications

Amy B Heimberger